Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTH1 siRNA
- Development stage
- Preclinical
- Lead developer
- Universitätsklinikum Köln
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
MTH1 siRNA is a small interfering RNA designed to silence the expression of MutT homolog 1 (MTH1), also known as NUDT1. MTH1 is an enzyme that hydrolyzes oxidized purine nucleoside triphosphates (such as 8-oxo-dGTP), preventing their incorporation into DNA and subsequent DNA damage-induced apoptosis. In cancer cells, which often exhibit high levels of reactive oxygen species (ROS), MTH1 is frequently upregulated to maintain genomic integrity. Research, particularly from the University Hospital Cologne, has demonstrated that siRNA-mediated knockdown of MTH1 in glioblastoma multiforme (GBM) cells leads to impaired cell migration and reduced tumor growth in vivo.
- Other names
- MutT homolog 1 siRNANUDT1 siRNANUDT-1 siRNANUDT 1 siRNA
02
Targets
7,8-dihydro-8-oxoguanine triphosphatase mRNANUDT1 (Nudix hydrolase 1)
Beyond the preview
Go deeper on MTH1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MTH1 siRNA.